|EQA 2023 - Therapeutic Drug Monotoring (CMED)|
Expert Biologists - Scheme Coordinators:
Antony CITTERIO-QUENTIN and Sabine COHEN
EQA performed since 1993
Number of participating laboratories in 2022: 485
1 – Scheme overview
The goal of this scheme is twofold:
Longitudinal studies are carried out over several years to assess the popularity of the methods and their respective performances. Guidance and recommendations are issued with the results of these studies.
Participating labs can choose to be assessed for all the analytes of this scheme, or simply a subset of analytes of interest.
2 – Assessment frequency
Number of investigations per year: 4
Number of control samples per investigation: 1 or 2
Number of samples per year : 6
3 – List of analytes assessed
4 – Description of the control samples
Lyophilized human control serums (samples to be resuspended in 5 mL of distilled water).
|The sample matrix is not well suited for the determination of immunosuppressants (Ciclosporin and Tacrolimus). Between-method comparison is therefore not possible. However, their determination can be assessed using this scheme by comparison within each method group.|